Early halt for transplant lung disease drug trial
NCT ID NCT04239989
Summary
This early-stage study tested the safety of a drug called itacitinib for patients who developed a serious lung scarring condition (bronchiolitis obliterans) after a donor stem cell transplant. The trial aimed to see if the drug could help control this complication and improve patients' breathing and quality of life. It was a small, Phase 1 study that was later terminated.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIOLITIS OBLITERANS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.